REGULATORY INTELLIGENCE·Warning Letter
FDA Identifies Critical Processing Control Deficiencies at AEQUITA PHARMACY, Triggering Semaglutide Recall
AEQUITA PHARMACY initiated a Class II recall for 176 vials of Semaglutide + Cyanocobalamin injection solution due to a critical lack of processing controls at its Kirkland, WA facility. This event signals heightened FDA scrutiny on sterile compounding, necessitating immediate review of quality systems by procurement and regulatory teams across the chemical and life sciences industry.
90-Day Activity